ArticlePlastic and reconstructive surgery. Global open2026
Craniofacial Fracture and Secretome: A Systematic Review.
Article in Plastic and reconstructive surgery. Global open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Restoring normal morphology and function after craniofacial fractures remains a clinical challenge. Tissue engineering, particularly through cell-free approaches using secretome (soluble proteins and extracellular vesicles), has emerged as a promising strategy for enhancing bone regeneration. This study aims to evaluate the effectiveness of secretome therapy for craniofacial bone regeneration in animal and human models. Methods: This review was conducted in August 2024 using Google Scholar, The Cochrane Library, and PubMed. Inclusion criteria encompassed methodological studies (in vitro, in vivo, or clinical) with full-text availability. Studies on noncraniofacial fractures were excluded. The Cochrane risk of bias 2.0 checklist assessed risk of bias. Results: Of 20 included articles, 4 involved human studies (48 participants) and 16 used animal models: dogs (1 study, 4 dogs), rabbits (2 studies, 34 rabbits), and rats (13 studies, 281 rats). Secretome boosted levels of bone-healing proteins, including vascular endothelial growth factor, insulin-like growth factor, osteocalcin, transforming growth factor-beta 1, proliferating cell nuclear antigen, angiopoietin-1, angiopoietin-2, bone morphogenetic protein 2, matrix metalloproteinase 8, matrix metalloproteinase 13, integrin-binding sialoprotein, Runt-related transcription factor 2, and intercellular adhesion molecule 1. X rays, computed tomography, and histological analyses indicated that secretome therapy expedited bone healing. Conclusions: Secretome therapy enhances craniofacial bone healing by promoting the production of key cytokines and facilitating repair over large areas. Further research with larger sample sizes and reduced risk of bias is needed to strengthen these findings.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.